Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its ...

Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...

VistaGen Therapeutics, Inc. (NASDAQ ... We encourage you to review the release and our 10-Q, which can be found in the Investors section of our website. We will make forward-looking statements ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Matthew Kaplan; Analyst; Ladenburg Thalmann & Co. Inc Mayank Mamtani; Analyst; B. Riley Securities ...

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

The biopharmaceutical company posted revenue of $83.9 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $80.3 million. TG Therapeutics expects full-year ...

AM ETNEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

P4L AI users benefit from in-platform diamonds, which they will soon be able to convert into $P4L tokens. This planned ...